
Aneel A Ashrani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5327670/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination. JAMA Internal Medicine, 2022, 182, 80.	5.1	11
2	Persistence of Ad26.COV2.Sâ€associated vaccineâ€induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. American Journal of Hematology, 2022, 97, 519-526.	4.1	26
3	Risk of venous thromboembolism after COVIDâ€19 vaccination. Journal of Thrombosis and Haemostasis, 2022, 20, 1638-1644.	3.8	24
4	Leukocytosis and Tobacco Use: An Observational Study of Asymptomatic Leukocytosis. American Journal of Medicine, 2021, 134, e31-e35.	1.5	13
5	Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. Thrombosis Research, 2021, 207, 150-157.	1.7	24
6	Apixaban and dalteparin in active malignancyâ€associated venous thromboembolism: The ADAM VTE trial. Journal of Thrombosis and Haemostasis, 2020, 18, 411-421.	3.8	381
7	Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. European Journal of Haematology, 2020, 104, 88-96.	2.2	24
8	Portal Hypertensive Cholangiopathy, Which Masquerades as an Acute Portal Vein Thrombosis. Journal of Diagnostic Medical Sonography, 2020, 36, 182-185.	0.3	0
9	A study of dedicated haemophilia carrier clinics in the United States: Prevalence, services offered and barriers to development. Haemophilia, 2020, 26, e253-e255.	2.1	0
10	Continuous infusion of recombinant porcine factor VIII for neurosurgical management of intracranial haemorrhage in a patient with severe haemophilia A with factor VIII inhibitor. Haemophilia, 2020, 26, e141-e144.	2.1	0
11	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leukemia and Lymphoma, 2020, 61, 1592-1600.	1.3	17
12	Hemostatic prophylaxis and colonoscopy outcomes for patients with bleeding disorders: A retrospective cohort study and review of the literature. Haemophilia, 2020, 26, 257-268.	2.1	4
13	The differential diagnosis of basophilia in patients undergoing <scp>BCRâ€ABL</scp> testing. American Journal of Hematology, 2020, 95, E216-E217.	4.1	6
14	Evaluation of Soluble Fibrin Monomer Complex in Patients with Sars-Cov-2 COVID-19 Infection. Blood, 2020, 136, 27-28.	1.4	3
15	Thrombophilia Testing Practices: The Mayo Clinic Experience. Blood, 2020, 136, 39-40.	1.4	0
16	Reduced Calf Muscle Pump Function Is a Risk Factor for Venous Thromboembolism and Mortality. Blood, 2020, 136, 6-7.	1.4	0
17	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	3.0	6
18	47-Year-Old Man With Pancytopenia and Fever. Mayo Clinic Proceedings, 2019, 94, 1073-1078.	3.0	0

#	Article	IF	CITATIONS
19	Patterns and utility of vitamin B12 and folate testing in patients with isolated thrombocytopenia. Annals of Hematology, 2019, 98, 1993-1994.	1.8	2
20	Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism. Mayo Clinic Proceedings, 2019, 94, 1242-1252.	3.0	26
21	Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. British Journal of Haematology, 2019, 184, 1014-1017.	2.5	20
22	Incidental Pulmonary Embolism. Analysis of Mayo Clinic Venous Thromboembolism Database. Blood, 2019, 134, 1147-1147.	1.4	1
23	Desideromastica: Tactile Chew Cravings in Iron Deficiency Anemia. Blood, 2019, 134, 4815-4815.	1.4	Ο
24	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia, 2018, 32, 1414-1420.	7.2	20
25	Is Infection an Independent Risk Factor for Venous Thromboembolism? A Population-Based, Case-Control Study. American Journal of Medicine, 2018, 131, 307-316.e2.	1.5	40
26	Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The <scp>M</scp> ayo clinic experience with 84 consecutive cases. American Journal of Hematology, 2018, 93, E61-E64.	4.1	31
27	Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience. Thrombosis Research, 2018, 171, 14-21.	1.7	7
28	Thrombotic and hemorrhagic complications in children and young adult recipients of Hematopoietic Stem Cell Transplant (HSCT). Thrombosis Research, 2018, 167, 44-49.	1.7	4
29	Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis. American Journal of Hematology, 2018, 93, E235-E238.	4.1	8
30	Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study. Blood, 2018, 132, 5067-5067.	1.4	2
31	Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience. Blood, 2018, 132, 2525-2525.	1.4	3
32	Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial. Blood, 2018, 132, 421-421.	1.4	36
33	Inpatient Outcomes and Rates of Venous Thromboembolism and Gastrointestinal Hemorrhage in Patients with Gastric Cancer: Results from Nationwide Inpatient Sample Database 2009-2014. Blood, 2018, 132, 5882-5882.	1.4	0
34	Efficacy and Safety of Prothrombin Complex Concentrate (PCC) for Direct Oral Anticoagulant Reversal: A Single Institutional Experience. Blood, 2018, 132, 2533-2533.	1.4	0
35	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. American Journal of Hematology, 2017, 92, E164-E166.	4.1	5
36	The impact of postpartum hemorrhage on hospital length ofÂstay and inpatient mortality: a National Inpatient Sample–based analysis. American Journal of Obstetrics and Gynecology, 2017, 217, 344.e1-344.e6.	1.3	71

#	Article	IF	CITATIONS
37	Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. Vascular Medicine, 2017, 22, 121-127.	1.5	18
38	Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood, 2017, 130, 109-114.	1.4	90
39	von Willebrand disease type1/type 2N compound heterozygotes: diagnostic and management challenges. British Journal of Haematology, 2017, 176, 994-997.	2.5	4
40	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making. Journal of Women's Health, 2017, 26, 1350-1355.	3.3	0
41	Apixaban and dalteparin in active malignancy associated venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 1952-1961.	3.4	62
42	Reasons for the persistent incidence of venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 390-400.	3.4	89
43	Smoldering Waldenström's macroglobulinemia (SWM): Analysis from the National Cancer Database (NCDB) Journal of Clinical Oncology, 2017, 35, 1573-1573.	1.6	0
44	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. Blood, 2017, 130, 927-927.	1.4	0
45	Spur cell anemia in the setting of progressive liver allograft failure. American Journal of Hematology, 2016, 91, 1061-1061.	4.1	2
46	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	3.0	55
47	Risk factors for incident venous thromboembolism in active cancer patients: A population based case–control study. Thrombosis Research, 2016, 139, 29-37.	1.7	58
48	Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry. American Journal of Medicine, 2016, 129, 615-619.	1.5	60
49	Direct Medical Costs Attributable to Cancer-Associated Venous Thromboembolism: A Population-Based Longitudinal Study. American Journal of Medicine, 2016, 129, 1000.e15-1000.e25.	1.5	28
50	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. Blood, 2016, 128, 2451-2451.	1.4	1
51	Prevalence and survival of smoldering multiple myeloma in the US: Analysis using a national dataset Journal of Clinical Oncology, 2016, 34, 8035-8035.	1.6	0
52	Sex-Based Disparities in Venous Thromboembolism Sociodemographics and Outcomes: A National Inpatient Sample (NIS)-Based Analysis. Blood, 2016, 128, 5918-5918.	1.4	1
53	The Impact of Antithrombin Deficiency on Women's Reproductive Health Experiences and Healthcare Decision-Making: A Qualitative Patient-Oriented Survey Study. Blood, 2016, 128, 3588-3588.	1.4	0
54	Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients. British Journal of Haematology, 2015, 171, 875-879.	2.5	5

#	Article	IF	CITATIONS
55	Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1079-1095.	4.9	100
56	Direct medical costs attributable to venous thromboembolism among persons hospitalized for major operation: A population-based longitudinal study. Surgery, 2015, 157, 423-431.	1.9	26
57	Pulmonary Infarction Manifesting as a Cavitary Lesion. Mayo Clinic Proceedings, 2015, 90, 1170.	3.0	Ο
58	Risk of site-specific cancer in incident venous thromboembolism: A population-based study. Thrombosis Research, 2015, 135, 472-478.	1.7	61
59	Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case–control study. Thrombosis Research, 2015, 135, 1110-1116.	1.7	16
60	Predictors of Venous Thromboembolism Recurrence, Adjusted for Treatments and Interim Exposures: A Population-based Case-cohort Study. Thrombosis Research, 2015, 136, 298-307.	1.7	40
61	Incidence of symptomatic venous thromboembolism in patients with hemophilia undergoing joint replacement surgery: A retrospective study. Thrombosis Research, 2015, 135, 109-113.	1.7	36
62	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath. Blood, 2015, 126, 1050-1050.	1.4	3
63	Abstract 303: Risk Factors for Venous Thromboembolism (VTE) among Patients with Neurologic Disease and Leg Paresis: A Population-based Case-control Study Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	Ο
64	Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood, 2014, 123, 3972-3978.	1.4	167
65	Rethinking Guidelines for VTE Risk Among Nursing Home Residents. Chest, 2014, 146, 412-421.	0.8	9
66	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. Blood, 2013, 122, 5000-5000.	1.4	0
67	Autoimmunity in Patients (pts) with Chronic Myelomonocytic Leukemia (CMML): A Frequent Finding. Blood, 2012, 120, 4930-4930.	1.4	3
68	Trends in the Incidence of Venous Thromboembolism Adjusted for Body Mass Index (BMI) Blood, 2012, 120, 2256-2256.	1.4	0
69	Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood, 2011, 118, 4992-4999.	1.4	67
70	Impact of Interim Hospitalizations on Risk of Venous Thromboembolism (VTE) Recurrence: A Nested Case-Cohort Study. Blood, 2011, 118, 1241-1241.	1.4	0
71	Hemolytic Anemia Following Intravenous Immunoglobulin Administration: A Cluster of Suspected Cases. Blood, 2011, 118, 4332-4332.	1.4	0
72	Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: A nested case-control study. Vascular Medicine, 2010, 15, 387-397.	1.5	25

#	Article	IF	CITATIONS
73	Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thrombosis Research, 2010, 126, 373-378.	1.7	83
74	Are Beta-Receptor and Angiotensin-Blocking Drugs Protective Against Venous Thromboembolism (VTE)? A Population Based Case-Control Study. Blood, 2010, 116, 5118-5118.	1.4	0
75	Risk Factors for Venous Thromboembolism (VTE) Among Nursing Home Residents: A Population-Based Case Control Study. Blood, 2010, 116, 476-476.	1.4	1
76	Risk factors and underlying mechanisms for venous stasis syndrome: a population-based case–control study. Vascular Medicine, 2009, 14, 339-349.	1.5	26
77	Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1399-1405.	2.4	101
78	Incidence and cost burden of post-thrombotic syndrome. Journal of Thrombosis and Thrombolysis, 2009, 28, 465-476.	2.1	230
79	Chemotherapy-Associated Thrombosis. Cancer Treatment and Research, 2009, 148, 181-206.	0.5	8
80	Risk Factors for Thrombosis in Cancer Patients. Cancer Treatment and Research, 2009, 148, 95-114.	0.5	4
81	Odds of Venous Thromboembolims (VTE) Associated with Hospitalization, Surgery, and Cancer Among Nursing Home Residents: A Population-Based Study Blood, 2009, 114, 2984-2984.	1.4	28
82	Incidence of Cancer-Associated Venous Thromboembolism (VTE): A Population-Based Cohort Study. Blood, 2008, 112, 3822-3822.	1.4	1
83	Role of Venous Outflow Obstruction and Venous Valvular Incompetence as Mechanisms for Venous Stasis Syndrome Following Deep Vein Thrombosis: A Population-Based Cohort Study Blood, 2006, 108, 1495-1495.	1.4	2